Last reviewed · How we verify
FOLFOX chemotherapy regimens
FOLFOX is a combination chemotherapy regimen that uses 5-fluorouracil and leucovorin to inhibit thymidylate synthase and DNA synthesis, combined with oxaliplatin to create DNA crosslinks and prevent replication.
FOLFOX is a combination chemotherapy regimen that uses 5-fluorouracil and leucovorin to inhibit thymidylate synthase and DNA synthesis, combined with oxaliplatin to create DNA crosslinks and prevent replication. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer, Gastric cancer.
At a glance
| Generic name | FOLFOX chemotherapy regimens |
|---|---|
| Also known as | CapeOx regimens |
| Sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
| Drug class | Combination chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX (5-Fluorouracil, Leucovorin, and Oxaliplatin) is a multi-drug chemotherapy regimen where 5-FU acts as an antimetabolite that disrupts nucleotide synthesis, leucovorin enhances 5-FU activity by stabilizing its binding to thymidylate synthase, and oxaliplatin is a platinum-based alkylating agent that forms DNA adducts. Together, these agents work synergistically to induce apoptosis in rapidly dividing cancer cells.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colon cancer
- Gastric cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Mucositis
- Fatigue
Key clinical trials
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (NA)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: